Study of Chemoimmunotherapy for High-Risk Neuroblastoma

NCT03189706 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma (NB)

Interventions

DRUG: Irinotecan
DRUG: temozolomide
BIOLOGICAL: Hu3F8
DRUG: GM-CSF

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]